Top Markets
#1 Derive Derive +36.07%
#2 Cross Cross +18.56%
#3 The Bitcoin Bull The Bitcoin Bull +14.92%
#4 Geodnet Geodnet +10.04%
#5 Gama Token Gama Token +9.18%
#6 Biconomy Biconomy +8.72%
#7 Starpower Starpower +7.90%
#8 Humanity Humanity +7.57%
#9 Steakhouse ETH Morpho Vault Steakhouse ETH Morpho Vault +6.71%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +6.64%
Coin of the day
Derive Derive
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Moleculin Biotech, Inc. Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

MBRX
Rangering i aksjer #35911
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to... Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
Aksjekurs
$0.6155
Sist synkronisert: 2026-08-14
Markedsverdi
$3.28M
Endring (1 dag)
7.74%
Endring (1 år)
-96.39%
Land
US
Handel Moleculin Biotech, Inc. (MBRX)

Kategori

Healthcare
P/E-forhold for Moleculin Biotech, Inc. (MBRX)
P/E-forhold per 2026 TTM: 0
Ifølge Moleculin Biotech, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Moleculin Biotech, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.